00:54:17	Lily Hoffman-Andrews:	Do you see a disconnect between patient’s (and/or clinician’s) beliefs about what this testing can do and its actual utility/evidence base, and if so how do you feel about the ethics of that?
00:54:51	Alex Truhlar:	Brothers et al., 2024: Moving to the “Middle Ground”: Redefining Genomic Utility to Expand Understanding of Familial Benefit https://pmc.ncbi.nlm.nih.gov/articles/PMC11173350/
00:55:25	Alex Truhlar:	Reacted to "Do you see a disconn..." with 👍🏼
00:59:28	Lily Hoffman-Andrews:	Thanks Dr. Hendy for your thoughtful answer and a great talk!
00:59:42	Jeri Nichols (GenePharmer, LLC):	Interestingly, pharmacists working in psychiatry have noted that patients who have a lot of "drug allergies" have a diagnosis of borderline personality disorder.  I would love to see someone do PGx on these patients. Also, really enjoyed this!
01:00:18	Alex Truhlar:	Reacted to "Interestingly, pharm..." with 👍🏼
01:00:35	Eleanor Griffith, MS, CGC:	Reacted to "Interestingly, pharm..." with 👍🏼
01:00:36	Elise Li Zheng:	Is there circumstances that the test cannot explain what patients have experienced, or even goes against? What are the strategies for making valid narratives around the test?
01:00:55	Ginger Nichols:	I'm sorry if I missed this -but how many of the patients were female and how many were male, and were you able see a difference in how the HCP approached a female versus male patient? (maybe not available with only 10)
01:01:11	Liz Charnysh:	Reacted to "Interestingly, pharm..." with 👍
01:04:40	Kelsey Zegar:	With some patients getting stuck in those bucket-style results, do you think that genotype results might be received better? Do you have any concerns that the current results presentation might only be used as a current snapshot based on current knowledge? Whereas genotypes can be referenced over and over as evidence builds and new medications are developed and studied.
01:06:00	Bridget Blevins:	i find this testing super interesting and have done it myself, but my provider did not warn me of the OOP cost so the $300 some dollars was not a fun surprise. do you find that most providers do warn their patients of the cost?
01:06:02	Kyle Davis:	Thanks for your talk and great work on the project! I have a question about the "middle ground utility": Since payors and institutions often focus on clinical utility, do you think this concept of middle ground utility, especially for something like PGx (which as high clinical utility in some instances) is detrimental to continued PGx research and improvement of these tests? It seems like this concept is great for academia, but not great for patients and clinical research.
01:08:52	Eve Plank MPH,MSW (she/her):	Reacted to "With some patients g..." with ❗